{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:34:10Z","timestamp":1773408850065,"version":"3.50.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.bbr.2014.11.001","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T09:14:12Z","timestamp":1416302052000},"page":"191-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with \u03b1-synuclein aggregates which incite parkinsonian-like symptoms"],"prefix":"10.1016","volume":"279","author":[{"given":"Marina A.","family":"Gruden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana V.","family":"Davydova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor B.","family":"Narkevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina G.","family":"Fomina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir S.","family":"Kudrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmilla A.","family":"Morozova-Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1702-5100","authenticated-orcid":false,"given":"Robert D.E.","family":"Sewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2014.11.001_bib0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2741\/S415","article-title":"Parkinson's disease: a review","volume":"6","author":"Beitz","year":"2014","journal-title":"Front Biosci (Schol Ed)"},{"key":"10.1016\/j.bbr.2014.11.001_bib0010","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/mds.23669","article-title":"Milestones in Parkinson's disease - clinical and pathologic features","volume":"26","author":"Halliday","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2014.11.001_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mds.25273","article-title":"Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials","volume":"28","author":"Kalia","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2014.11.001_bib0020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bbr.2014.11.001_bib0025","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00401-012-0963-y","article-title":"Nigrostriatal overabundance of \u03b1-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity","volume":"123","author":"Gaugler","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrn983","article-title":"Pathogenesis of Parkinson's disease: dopamine, vesicles and \u03b1- synuclein","volume":"3","author":"Lotharius","year":"2002","journal-title":"Nature Rev Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.pneurobio.2011.08.004","article-title":"The serotonergic system in Parkinson's disease","volume":"95","author":"Huot","year":"2011","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0040","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.febslet.2011.03.009","article-title":"Synuclein modulation of monoamine transporters","volume":"585","author":"Oaks","year":"2011","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.bbr.2014.11.001_bib0045","doi-asserted-by":"crossref","first-page":"e26794","DOI":"10.4161\/cib.26794","article-title":"Parallel mechanisms for direct and indirect membrane protein trafficking by synucleins","volume":"6","author":"Oaks","year":"2013","journal-title":"Commun Integr Biol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.25373","article-title":"Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?","volume":"28","author":"Olanow","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.bbr.2014.11.001_bib0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0304-3940(03)00097-1","article-title":"Attenuation of dopamine transporter activity by alpha-synuclein","volume":"340","author":"Wersinger","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.11.001_bib0060","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1096\/fj.03-0152fje","article-title":"Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress","volume":"17","author":"Wersinger","year":"2003","journal-title":"Faseb J"},{"key":"10.1016\/j.bbr.2014.11.001_bib0065","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1111\/j.1460-9568.2006.05181.x","article-title":"Attenuation of the norepinephrine transporter activity and trafficking via interactions with alpha-synuclein","volume":"24","author":"Wersinger","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1460-9568.2006.04900.x","article-title":"Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein","volume":"24","author":"Wersinger","year":"2006","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0075","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1460-9568.2007.05757.x","article-title":"Regulation of the norepinephrine transporter by alpha-synuclein-mediated interactions with microtubules","volume":"26","author":"Jeannotte","year":"2007","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1468-1331.2009.02900.x","article-title":"Neurotransmission in Parkinson's disease: beyond dopamine","volume":"17","author":"Barone","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0085","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jneuroim.2010.12.001","article-title":"Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression","volume":"233","author":"Gruden","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbr.2014.01.017","article-title":"Intranasal administration of alpha-synuclein aggregates: a Parkinson's disease model with behavioral and neurochemical correlates","volume":"263","author":"Gruden","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.11.001_bib0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/138920308785915218","article-title":"Alpha-synuclein misfolding and neurodegenerative diseases","volume":"9","author":"Uversky","year":"2008","journal-title":"Curr Protein Peptide Sci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138920309789351921","article-title":"Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein","volume":"10","author":"Uversky","year":"2009","journal-title":"Curr Protein Peptide Sci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0105","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.patbio.2014.01.003","article-title":"Protein aggregation and prionopathies","volume":"62","author":"Renner","year":"2014","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.bbr.2014.11.001_bib0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/pri.28125","article-title":"In vitro aggregation assays for the characterization of \u03b1-synuclein prion-like properties","volume":"8","author":"Narkiewicz","year":"2014","journal-title":"Prion"},{"key":"10.1016\/j.bbr.2014.11.001_bib0115","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nrneurol.2013.275","article-title":"\u03b1-synuclein - a novel and crucial factor in Lewy body diseases","volume":"10","author":"Lee","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0120","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","article-title":"Presynaptic \u03b1-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies","volume":"27","author":"Kramer","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0125","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1100\/2011\/172893","article-title":"Serotonergic dysfunction in Parkinson's disease and its relevance to disability","volume":"11","author":"Politis","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.bbr.2014.11.001_bib0130","article-title":"Serotonin in Parkinson's disease","author":"Politis","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.11.001_bib0135","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbr.2013.01.011","article-title":"Nasal inoculation with \u03b1-synuclein aggregates evokes rigidity, locomotor deficits and immunity to such misfolded species as well as dopamine","volume":"243","author":"Gruden","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.11.001_bib0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat Protoc"},{"key":"10.1016\/j.bbr.2014.11.001_bib0145","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0166-4328(01)00309-6","article-title":"Behavioral phenotyping of the MPTP mouse model of Parkinson's disease","volume":"125","author":"Sedelis","year":"2001","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.bbr.2014.11.001_bib0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1006\/exnr.2002.8021","article-title":"Detection of behavioural impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"178","author":"Tillerson","year":"2002","journal-title":"Exp Neurol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0928-4680(96)00160-5","article-title":"Effects of fibroblast growth factors on MPTP-induced parkinsonian syndrome in mice","volume":"4","author":"Kryzhanovsky","year":"1997","journal-title":"Pathophysiology"},{"key":"10.1016\/j.bbr.2014.11.001_bib0160","first-page":"219","article-title":"Some observations on the effects of two enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine","volume":"256","author":"Ben-Sreti","year":"1982","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"10.1016\/j.bbr.2014.11.001_bib0165","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/3311","article-title":"Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease","volume":"4","author":"Conway","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.bbr.2014.11.001_bib0170","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-2836(02)00775-1","article-title":"Dependence of alpha-synuclein aggregate morphology on solution conditions","volume":"322","author":"Hoyer","year":"2002","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0175","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1006\/jsbi.2000.4264","article-title":"Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants","volume":"130","author":"Morozova-Roche","year":"2000","journal-title":"J Struct Biol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/pro.5560020312","article-title":"Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution","volume":"2","author":"LeVine","year":"1993","journal-title":"Protein Sci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0185","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0022-2836(03)00551-5","article-title":"Amyloid protofilaments from the calcium-binding protein equine lysozyme: formation of ring and linear structures depends on pH and metal ion concentration","volume":"330","author":"Malisauskas","year":"2003","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0190","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuroscience.2011.03.007","article-title":"Modeling of presymptomatic and symptomatic stages of parkinsonism in mice","volume":"181","author":"Ugrumov","year":"2011","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.bbr.2014.11.001_bib0195","doi-asserted-by":"crossref","first-page":"e90857","DOI":"10.1371\/journal.pone.0090857","article-title":"A generic method for design of oligomer-specific antibodies","volume":"9","author":"Br\u00e4nnstr\u00f6m","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2014.11.001_bib0200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0072-9752(08)02133-7","article-title":"Chapter 33: The history of movement disorders","volume":"95","author":"Lanska","year":"2010","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0205","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/cercor\/bht058","article-title":"Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson's disease: clues from dyskinetic patients","volume":"24","author":"Kishore","year":"2014","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.bbr.2014.11.001_bib0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2990.1983.tb00320.x","article-title":"Pathological basis for neurotransmitter changes in Parkinson's disease","volume":"9","author":"Mann","year":"1983","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0215","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2990.2004.00558.x","article-title":"Protein misfolding in neurodegenerative diseases","volume":"30","author":"Agorogiannis","year":"2004","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"10.1016\/j.bbr.2014.11.001_bib0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neurol.2013.11.002","article-title":"Protein folding and misfolding in the neurodegenerative disorders: a review","volume":"170","author":"Bolshette","year":"2014","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.bbr.2014.11.001_bib0225","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jmb.2012.01.006","article-title":"Oligomeric intermediates in amyloid formation: structure determination and mechanisms of toxicity","volume":"421","author":"F\u00e4ndrich","year":"2012","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0230","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0235","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1096\/fj.00-0334com","article-title":"Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis","volume":"15","author":"Lee","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.bbr.2014.11.001_bib0240","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuro.2004.05.002","article-title":"Mice lacking alpha-synuclein have an attenuated loss of striatal dopamine following prolonged chronic MPTP administration","volume":"25","author":"Drolet","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bbr.2014.11.001_bib0245","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12640-011-9281-8","article-title":"Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease","volume":"21","author":"Prediger","year":"2012","journal-title":"Neurotox Res"},{"key":"10.1016\/j.bbr.2014.11.001_bib0250","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/187152710791556177","article-title":"MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach","volume":"9","author":"Bazzu","year":"2010","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"12","key":"10.1016\/j.bbr.2014.11.001_bib0255","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.neurobiolaging.2008.11.010","article-title":"Selective noradrenergic vulnerability in \u03b1-synuclein transgenic mice","volume":"31","author":"Sotiriou","year":"2010","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.bbr.2014.11.001_bib0260","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.parkreldis.2011.05.012","article-title":"Serotonin and dopamine striatal innervation in Parkinson and Huntington's chorea","volume":"17","author":"B\u00e9dard","year":"2011","journal-title":"Parkinsonism Related Disord"},{"key":"10.1016\/j.bbr.2014.11.001_bib0265","doi-asserted-by":"crossref","first-page":"20051","DOI":"10.1073\/pnas.0908005106","article-title":"Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells","volume":"106","author":"Luk","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0270","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","article-title":"Different species of alpha-synuclein oligomers induce calcium influx and seeding","volume":"27","author":"Danzer","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0275","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/iub.316","article-title":"Oligomeric alpha-synuclein and its role in neuronal death","volume":"62","author":"Brown","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bbr.2014.11.001_bib0280","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1385\/NMM:4:1-2:21","article-title":"Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases","volume":"4","author":"Hashimoto","year":"2003","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.bbr.2014.11.001_bib0285","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1021\/bi0102398","article-title":"Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease","volume":"40","author":"Volles","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbr.2014.11.001_bib0290","series-title":"Protein Misfolding in Neurodegenerative Diseases","first-page":"1","article-title":"Protein folding and misfolding, relevance to disease and biological function","author":"Stefani","year":"2008"},{"key":"10.1016\/j.bbr.2014.11.001_bib0295","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pneurobio.2013.10.004","article-title":"Autophagy and apoptosis dysfunction in neurodegenerative disorders","volume":"112","author":"Ghavami","year":"2014","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0300","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/j.1471-4159.2007.04933.x","article-title":"Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers","volume":"103","author":"Danzer","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.11.001_bib0305","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.neulet.2008.02.014","article-title":"Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice","volume":"435","author":"Alerte","year":"2008","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.11.001_bib0310","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1471-4159.2006.04146.x","article-title":"Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells","volume":"99","author":"Tehranian","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.11.001_bib0315","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00401-007-0260-3","article-title":"Rostral raphe involvement in Lewy body dementia and multiple system atrophy","volume":"114","author":"Benarroch","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bbr.2014.11.001_bib0320","doi-asserted-by":"crossref","first-page":"11165","DOI":"10.1523\/JNEUROSCI.2559-04.2004","article-title":"Role of alpha-synuclein in presynaptic dopamine recruitment","volume":"24","author":"Yavich","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0325","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1471-4159.2006.04098.x","article-title":"Abnormal compartmentalization of norepinephrine in mouse dentate gyrus in alpha-synuclein knockout and A30P transgenic mice","volume":"99","author":"Yavich","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.11.001_bib0330","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.neulet.2005.11.068","article-title":"Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra","volume":"396","author":"Yamamoto","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.bbr.2014.11.001_bib0335","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","article-title":"Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein","volume":"22","author":"Cabin","year":"2002","journal-title":"J Neurosci."},{"key":"10.1016\/j.bbr.2014.11.001_bib0340","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1044-7431(03)00124-6","article-title":"Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity","volume":"24","author":"Wersinger","year":"2003","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.bbr.2014.11.001_bib0345","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/j.1471-4159.2008.05258.x","article-title":"Regulated interactions of the norepineprhine transporter by the actin and microtubule cytoskeletons","volume":"105","author":"Jeannotte","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.bbr.2014.11.001_bib0350","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1017\/S0033583506004422","article-title":"Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?","volume":"39","author":"Lashuel","year":"2006","journal-title":"Q Rev Biophys"}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281400727X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016643281400727X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:18:10Z","timestamp":1717546690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016643281400727X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":70,"alternative-id":["S016643281400727X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2014.11.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725257534.793502256","asserted-by":"object"}]},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noradrenergic and serotonergic neurochemistry arising from intranasal inoculation with \u03b1-synuclein aggregates which incite parkinsonian-like symptoms","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2014.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}